Verastem (VSTM) 2025 Conference June 04, 2025 04:20 PM ET Speaker0 One of the biotech analysts are here. Please join me and welcome Mr. Dan Patterson, CEO from Verastem for this FerroSat chat session. Welcome, Dan. Speaker1 Thanks. Great to be here. Speaker0 And congratulations on the recent approval for low grade SARS ovarian cancer. Before we get into details, maybe you could give us a brief intro for the company Verastem and this novel combo, the recent approval and your interesting pipeline. Speaker1 Su ...

Verastem (VSTM) 2025 Update / Briefing June 02, 2025 12:00 PM ET Speaker0 Thanks everybody for coming. Very excited You're familiar with our story. We're really focused on RAFmAbK driven cancers. Within our own portfolio, we've got the RAFmec inhibitor of vutametinib, defactinib, which is our FAC inhibitor and then the G12D inhibitor. In addition to that, we do have two other targets as part of our Genfleet collaboration that we haven't disclosed. And so both within our own portfolio and then combining with ...